Member-only story
In October, the U.S. International Trade Commission (ITC) ruled that Apple’s Apple Watch products infringed medical device maker Masimo’s patents for measuring blood oxygen saturation. As a result, Apple had to suspend the sale of the Apple Watch Series 10 and Ultra 12 models in the U.S. market on December 21.
However, after Apple appealed, the company obtained a stay of execution of the ITC injunction, which allowed the Apple Watch Series 9 and Ultra 2, which had been banned from sale, to resume sales only temporarily.
Masimo’s innovative oxygen saturation measurement feature has been the foundation of its success. On the other hand, Apple’s purported poaching of Masimo’s engineers threatens to undercut their innovation and hard work.
In light of these charges, Apple must acknowledge and show due respect to Masimo’s intellectual property rights. As a company that prides itself on innovation and progress, Apple must ensure that it does not infringe on the hard work and creativity of others in the industry. By honoring the intellectual property rights of Masimo, Apple still has the option to demonstrate its commitment to fair competition and pave…
